Mouwasat 2023 profit up 10% to SAR 657.7M; Q4 at SAR 184.2M

24/03/2024 Argaam Exclusive

View other reports

Mouwasat Medical Services Co.’s net profit grew 10% to SAR 657.7 million for 2023, from SAR 599.3 million in 2022.

Financials (M)

Item	2022	2023	Change‬
Revenues	2,334.11	2,705.51	15.9 %
Gross Income	1,101.57	1,313.08	19.2 %
Operating Income	665.72	748.18	12.4 %
Net Income	599.31	657.69	9.7 %
Average Shares	200.00	200.00	-
EPS (Riyals)	3.00	3.29	9.7 %

The medical services provider reported revenues of SAR 2.70 billion for 2023, up 15.9% year-on-year (YoY). This was driven by the higher number of outpatients and inpatients due to the launch of new projects during the second half of 2022.

The company also cited the continuous improvement in the performance of hospitals' newly-specialized departments and the ongoing enhancement of operating efficiency of the available resources.

The gross profit margin rose to 48.5% in 2023, compared with 47.2% a year before. Other revenues also went up YoY.

In Q4 2023, net profit fell 0.7% to SAR 184.2 million, from SAR 185.4 million in Q4 2022.

Compared to the previous quarter, Q4 net profit climbed 17.8% from SAR 156.38 million.

Current Quarter Comparison (M)

Compared With The

Item	Q4 2022	Q4 2023	Change‬
Revenues	660.14	773.06	17.1 %
Gross Income	328.64	394.57	20.1 %
Operating Income	211.45	201.69	(4.6 %)
Net Income	185.40	184.17	(0.7 %)
Average Shares	200.00	200.00	-
EPS (Riyals)	0.93	0.92	(0.7 %)

Item	Q3 2023	Q4 2023	Change‬
Revenues	640.89	773.06	20.6 %
Gross Income	298.26	394.57	32.3 %
Operating Income	182.40	201.69	10.6 %
Net Income	156.38	184.17	17.8 %
Average Shares	200.00	200.00	-
EPS (Riyals)	0.78	0.92	17.8 %

Shareholders’ equity, after minority interest, rose to SAR 3.27 billion as of Dec. 31, 2023, from SAR 2.92 billion a year earlier.

View More Financial Results

Financial results (Million)

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
Q1 2014	243.54	11.1 %	124.18	12.5 %	62.97	8.1 %
Q2 2014	244.25	6.8 %	124.14	6.2 %	63.22	5.4 %
Q3 2014	230.47	8.9 %	113.02	8.3 %	54.13	10.9 %
Q4 2014	247.18	1.9 %	117.49	(5.4 %)	52.86	(4.3 %)
2014	903.79	0.2 %	417.17	(8.5 %)	233.17	4.9 %
Q1 2015	253.41	4.1 %	118.63	(4.5 %)	62.06	(1.4 %)
Q2 2015	255.10	4.4 %	115.78	(6.7 %)	63.05	(0.3 %)
Q3 2015	231.63	0.5 %	98.68	(12.7 %)	49.14	(9.2 %)
Q4 2015	259.94	5.2 %	113.72	(3.2 %)	60.66	14.8 %
2015	1,000.08	10.7 %	446.81	7.1 %	234.90	0.7 %
Q1 2016	303.59	19.8 %	143.50	21.0 %	75.66	21.9 %
Q2 2016	300.21	17.7 %	139.76	20.7 %	71.70	13.7 %
Q3 2016	280.24	21.0 %	124.29	26.0 %	56.32	14.6 %
Q4 2016	359.19	38.2 %	168.91	48.5 %	84.39	39.1 %
2016	1,243.22	24.3 %	576.45	29.0 %	288.06	22.6 %
Q1 2017	362.97	19.6 %	173.37	20.8 %	93.17	23.1 %
Q2 2017	353.24	17.7 %	163.53	17.0 %	84.18	17.4 %
Q3 2017	359.47	28.3 %	164.38	32.3 %	85.84	52.4 %
Q4 2017	431.45	20.1 %	210.90	24.9 %	108.35	28.4 %
2017	1,507.14	21.2 %	712.17	23.5 %	371.53	29.0 %
Q1 2018	422.35	16.4 %	199.84	15.3 %	116.20	24.7 %
Q2 2018	394.35	11.6 %	185.90	13.7 %	98.77	17.3 %
Q3 2018	404.27	12.5 %	182.64	11.1 %	90.46	5.4 %
Q4 2018	456.04	5.7 %	205.12	(2.7 %)	98.62	(9.0 %)
2018	1,677.02	11.3 %	773.50	8.6 %	404.06	8.8 %
Q1 2019	462.62	9.5 %	211.32	5.7 %	122.04	5.0 %
Q2 2019	446.26	13.2 %	194.20	4.5 %	104.04	5.3 %
Q3 2019	443.29	9.7 %	193.64	6.0 %	104.74	15.8 %
Q4 2019	505.04	10.7 %	230.11	12.2 %	139.67	41.6 %
2019	1,857.21	10.7 %	829.27	7.2 %	470.49	16.4 %
Q1 2020	493.94	6.8 %	220.55	4.4 %	122.98	0.8 %
Q2 2020	468.43	5.0 %	219.01	12.8 %	131.19	26.1 %
Q3 2020	549.06	23.9 %	271.52	40.2 %	173.32	65.5 %
Q4 2020	533.60	5.7 %	249.21	8.3 %	150.35	7.6 %
2020	2,045.03	10.1 %	960.30	15.8 %	577.84	22.8 %
Q1 2021	534.12	8.1 %	254.30	15.3 %	158.49	28.9 %
Q2 2021	526.71	12.4 %	246.46	12.5 %	154.77	18.0 %
Q3 2021	530.98	(3.3 %)	244.40	(10.0 %)	150.10	(13.4 %)
Q4 2021	552.33	3.5 %	250.62	0.6 %	158.56	5.5 %
2021	2,144.14	4.8 %	995.78	3.7 %	621.93	7.6 %
Q1 2022	566.97	6.1 %	267.78	5.3 %	159.68	0.8 %
Q2 2022	557.86	5.9 %	258.09	4.7 %	155.34	0.4 %
Q3 2022	549.15	3.4 %	247.06	1.1 %	139.25	(7.2 %)
Q4 2022	660.14	19.5 %	328.64	31.1 %	211.45	33.4 %
2022	2,334.11	8.9 %	1,101.57	10.6 %	665.72	7.0 %
Q1 2023	664.22	17.2 %	328.39	22.6 %	192.98	20.9 %
Q2 2023	627.34	12.5 %	293.03	13.5 %	172.27	10.9 %
Q3 2023	640.89	16.7 %	298.26	20.7 %	182.40	31.0 %
Q4 2023	773.06	17.1 %	394.57	20.1 %	201.69	(4.6 %)
2023	2,705.51	15.9 %	1,313.08	19.2 %	748.18	12.4 %

Period	Revenues	Change	Gross Income	Change	Operating Income	Change
2014	903.79	0.2 %	417.17	(8.5 %)	233.17	4.9 %
2015	1,000.08	10.7 %	446.81	7.1 %	234.90	0.7 %
2016	1,243.22	24.3 %	576.45	29.0 %	288.06	22.6 %
2017	1,507.14	21.2 %	712.17	23.5 %	371.53	29.0 %
2018	1,677.02	11.3 %	773.50	8.6 %	404.06	8.8 %
2019	1,857.21	10.7 %	829.27	7.2 %	470.49	16.4 %
2020	2,045.03	10.1 %	960.30	15.8 %	577.84	22.8 %
2021	2,144.14	4.8 %	995.78	3.7 %	621.93	7.6 %
2022	2,334.11	8.9 %	1,101.57	10.6 %	665.72	7.0 %
2023	2,705.51	15.9 %	1,313.08	19.2 %	748.18	12.4 %

Profit Performance (Million)

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
Q1 2014	57.94	10.3 %	0.29	-	57.94	0.29
Q2 2014	59.44	9.8 %	0.30	-	59.44	0.30
Q3 2014	71.99	63.2 %	0.36	21.70	50.29	0.25
Q4 2014	50.75	0.7 %	0.25	2.20	48.55	0.24
2014	240.12	19.3 %	1.20	23.90	216.22	1.08
Q1 2015	55.93	(3.5 %)	0.28	-	55.93	0.28
Q2 2015	56.09	(5.6 %)	0.28	-	56.09	0.28
Q3 2015	42.99	(40.3 %)	0.21	-	42.99	0.21
Q4 2015	53.80	6.0 %	0.27	-	53.80	0.27
2015	208.80	(13.0 %)	1.04	-	208.80	1.04
Q1 2016	68.47	22.4 %	0.34	-	68.47	0.34
Q2 2016	63.70	13.6 %	0.32	-	63.70	0.32
Q3 2016	49.36	14.8 %	0.25	-	49.36	0.25
Q4 2016	75.65	40.6 %	0.38	-	75.65	0.38
2016	257.18	23.2 %	1.29	-	257.18	1.29
Q1 2017	85.12	24.3 %	0.43	-	85.12	0.43
Q2 2017	76.34	19.8 %	0.38	-	76.34	0.38
Q3 2017	76.73	55.4 %	0.38	-	76.73	0.38
Q4 2017	98.55	30.3 %	0.49	-	98.55	0.49
2017	336.73	30.9 %	1.68	-	336.73	1.68
Q1 2018	106.01	24.5 %	0.53	-	106.01	0.53
Q2 2018	87.88	15.1 %	0.44	-	87.88	0.44
Q3 2018	80.89	5.4 %	0.40	-	80.89	0.40
Q4 2018	85.43	(13.3 %)	0.43	-	85.43	0.43
2018	360.21	7.0 %	1.80	-	360.21	1.80
Q1 2019	107.22	1.1 %	0.54	-	107.22	0.54
Q2 2019	90.31	2.8 %	0.45	-	90.31	0.45
Q3 2019	93.04	15.0 %	0.47	-	93.04	0.47
Q4 2019	130.47	52.7 %	0.65	-	130.47	0.65
2019	421.03	16.9 %	2.11	-	421.03	2.11
Q1 2020	108.03	0.8 %	0.54	-	108.03	0.54
Q2 2020	115.73	28.2 %	0.58	-	115.73	0.58
Q3 2020	161.10	73.2 %	0.81	-	161.10	0.81
Q4 2020	143.30	9.8 %	0.72	-	143.30	0.72
2020	528.16	25.4 %	2.64	-	528.16	2.64
Q1 2021	147.19	36.3 %	0.74	-	147.19	0.74
Q2 2021	141.35	22.1 %	0.71	-	141.35	0.71
Q3 2021	142.66	(11.4 %)	0.71	-	142.66	0.71
Q4 2021	146.97	2.6 %	0.73	-	146.97	0.73
2021	578.16	9.5 %	2.89	-	578.16	2.89
Q1 2022	150.21	2.1 %	0.75	-	150.21	0.75
Q2 2022	141.48	0.1 %	0.71	-	141.48	0.71
Q3 2022	122.21	(14.3 %)	0.61	-	122.21	0.61
Q4 2022	185.40	26.2 %	0.93	-	185.40	0.93
2022	599.31	3.7 %	3.00	-	599.31	3.00
Q1 2023	166.61	10.9 %	0.83	-	166.61	0.83
Q2 2023	150.54	6.4 %	0.75	-	150.54	0.75
Q3 2023	156.38	28.0 %	0.78	-	156.38	0.78
Q4 2023	184.17	(0.7 %)	0.92	-	184.17	0.92
2023	657.69	9.7 %	3.29	-	657.69	3.29

Period	Net Income	Change	EPS(Riyal)	Extraordinary Income/Expense	Net Profit Before Unusual Items	EPS Before XO Items
2014	240.12	19.3 %	1.20	23.90	216.22	1.08
2015	208.80	(13.0 %)	1.04	-	208.80	1.04
2016	257.18	23.2 %	1.29	-	257.18	1.29
2017	336.73	30.9 %	1.68	-	336.73	1.68
2018	360.21	7.0 %	1.80	-	360.21	1.80
2019	421.03	16.9 %	2.11	-	421.03	2.11
2020	528.16	25.4 %	2.64	-	528.16	2.64
2021	578.16	9.5 %	2.89	-	578.16	2.89
2022	599.31	3.7 %	3.00	-	599.31	3.00
2023	657.69	9.7 %	3.29	-	657.69	3.29

Profitability

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2014	50.68 %	28.86 %	22.30 %
Q2 2014	50.62 %	28.77 %	22.49 %
Q3 2014	50.53 %	28.82 %	22.70 %
Q4 2014	49.60 %	28.54 %	22.40 %
2014	46.16 %	30.49 %	23.92 %
Q1 2015	48.53 %	28.38 %	21.96 %
Q2 2015	47.14 %	28.23 %	21.38 %
Q3 2015	45.64 %	28.05 %	20.62 %
Q4 2015	44.68 %	28.92 %	20.88 %
2015	44.68 %	28.92 %	20.88 %
Q1 2016	44.91 %	29.32 %	21.08 %
Q2 2016	45.25 %	29.52 %	20.90 %
Q3 2016	45.57 %	29.40 %	20.57 %
Q4 2016	46.37 %	29.27 %	20.69 %
2016	46.37 %	29.27 %	20.69 %
Q1 2017	46.55 %	29.66 %	21.02 %
Q2 2017	46.48 %	29.75 %	21.13 %
Q3 2017	46.71 %	30.51 %	21.87 %
Q4 2017	47.25 %	30.73 %	22.34 %
2017	47.25 %	30.73 %	22.34 %
Q1 2018	47.15 %	31.21 %	22.83 %
Q2 2018	47.34 %	31.39 %	22.96 %
Q3 2018	47.16 %	30.90 %	22.59 %
Q4 2018	46.12 %	30.64 %	21.48 %
2018	46.12 %	30.64 %	21.48 %
Q1 2019	45.71 %	30.83 %	21.05 %
Q2 2019	44.84 %	30.84 %	20.57 %
Q3 2019	44.48 %	31.47 %	20.79 %
Q4 2019	44.65 %	33.14 %	22.67 %
2019	44.65 %	33.14 %	22.67 %
Q1 2020	44.40 %	32.62 %	22.34 %
Q2 2020	45.18 %	33.87 %	23.41 %
Q3 2020	46.68 %	35.60 %	25.56 %
Q4 2020	46.96 %	35.51 %	25.83 %
2020	46.96 %	35.51 %	25.83 %
Q1 2021	47.67 %	36.72 %	27.21 %
Q2 2021	47.66 %	36.83 %	27.66 %
Q3 2021	46.79 %	36.14 %	27.03 %
Q4 2021	46.44 %	36.35 %	26.96 %
2021	46.44 %	36.35 %	26.96 %
Q1 2022	46.36 %	35.98 %	26.70 %
Q2 2022	46.23 %	35.59 %	26.33 %
Q3 2022	45.98 %	35.37 %	25.19 %
Q4 2022	47.19 %	36.60 %	25.68 %
2022	47.19 %	36.60 %	25.68 %
Q1 2023	47.80 %	37.06 %	25.32 %
Q2 2023	47.87 %	37.24 %	24.98 %
Q3 2023	48.15 %	37.76 %	25.42 %
Q4 2023	48.58 %	35.96 %	24.31 %
2023	48.53 %	35.91 %	24.31 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
2014	46.16 %	30.49 %	23.92 %
2015	44.68 %	28.92 %	20.88 %
2016	46.37 %	29.27 %	20.69 %
2017	47.25 %	30.73 %	22.34 %
2018	46.12 %	30.64 %	21.48 %
2019	44.65 %	33.14 %	22.67 %
2020	46.96 %	35.51 %	25.83 %
2021	46.44 %	36.35 %	26.96 %
2022	47.19 %	36.60 %	25.68 %
2023	48.53 %	35.91 %	24.31 %

Period	Gross Margin	OIBDA Margin	Net Margin Before Unusual Items
Q1 2014	50.99 %	29.94 %	23.79 %
Q2 2014	50.83 %	30.16 %	24.34 %
Q3 2014	49.04 %	27.98 %	21.82 %
Q4 2014	47.53 %	26.09 %	19.64 %
Q1 2015	46.81 %	29.28 %	22.07 %
Q2 2015	45.38 %	29.50 %	21.99 %
Q3 2015	42.60 %	27.19 %	18.56 %
Q4 2015	43.75 %	29.55 %	20.70 %
Q1 2016	47.27 %	30.60 %	22.55 %
Q2 2016	46.55 %	30.20 %	21.22 %
Q3 2016	44.35 %	27.12 %	17.62 %
Q4 2016	47.02 %	29.03 %	21.06 %
Q1 2017	47.76 %	31.79 %	23.45 %
Q2 2017	46.29 %	30.47 %	21.61 %
Q3 2017	45.73 %	30.75 %	21.34 %
Q4 2017	48.88 %	30.03 %	22.84 %
Q1 2018	47.32 %	33.44 %	25.10 %
Q2 2018	47.14 %	31.26 %	22.28 %
Q3 2018	45.18 %	28.81 %	20.01 %
Q4 2018	44.98 %	29.14 %	18.73 %
Q1 2019	45.68 %	33.91 %	23.18 %
Q2 2019	43.52 %	31.23 %	20.24 %
Q3 2019	43.68 %	31.56 %	20.99 %
Q4 2019	45.56 %	35.50 %	25.83 %
Q1 2020	44.65 %	31.90 %	21.87 %
Q2 2020	46.75 %	36.37 %	24.71 %
Q3 2020	49.45 %	38.37 %	29.34 %
Q4 2020	46.70 %	35.14 %	26.86 %
Q1 2021	47.61 %	36.88 %	27.56 %
Q2 2021	46.79 %	36.89 %	26.84 %
Q3 2021	46.03 %	35.66 %	26.87 %
Q4 2021	45.37 %	35.98 %	26.61 %
Q1 2022	47.23 %	35.41 %	26.49 %
Q2 2022	46.26 %	35.32 %	25.36 %
Q3 2022	44.99 %	34.77 %	22.25 %
Q4 2022	49.78 %	40.22 %	28.09 %
Q1 2023	49.44 %	37.27 %	25.08 %
Q2 2023	46.71 %	36.25 %	24.00 %
Q3 2023	46.54 %	37.22 %	24.40 %
Q4 2023	51.04 %	33.55 %	23.82 %

Per Share Data (Riyal)

Compared With The

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
Q1 2014	200.00	1.03	1.03	4.73
Q2 2014	200.00	1.06	1.06	4.53
Q3 2014	200.00	1.20	1.09	4.89
Q4 2014	200.00	1.20	1.08	5.14
Q1 2015	200.00	1.19	1.07	5.42
Q2 2015	200.00	1.17	1.05	5.20
Q3 2015	200.00	1.03	1.02	5.41
Q4 2015	200.00	1.04	1.04	5.67
Q1 2016	200.00	1.11	1.11	5.96
Q2 2016	200.00	1.14	1.14	5.84
Q3 2016	200.00	1.18	1.18	6.09
Q4 2016	200.00	1.29	1.29	6.38
Q1 2017	200.00	1.37	1.37	6.81
Q2 2017	200.00	1.43	1.43	6.57
Q3 2017	200.00	1.57	1.57	6.95
Q4 2017	200.00	1.68	1.68	7.45
Q1 2018	200.00	1.79	1.79	8.04
Q2 2018	200.00	1.85	1.85	7.73
Q3 2018	200.00	1.87	1.87	8.14
Q4 2018	200.00	1.80	1.80	8.56
Q1 2019	200.00	1.81	1.81	9.10
Q2 2019	200.00	1.82	1.82	8.68
Q3 2019	200.00	1.88	1.88	9.14
Q4 2019	200.00	2.11	2.11	9.78
Q1 2020	200.00	2.11	2.11	10.32
Q2 2020	200.00	2.24	2.24	9.90
Q3 2020	200.00	2.58	2.58	10.70
Q4 2020	200.00	2.64	2.64	11.40
Q1 2021	200.00	2.84	2.84	12.13
Q2 2021	200.00	2.96	2.96	11.59
Q3 2021	200.00	2.87	2.87	12.30
Q4 2021	200.00	2.89	2.89	13.02
Q1 2022	200.00	2.91	2.91	13.77
Q2 2022	200.00	2.91	2.91	13.10
Q3 2022	200.00	2.80	2.80	13.72
Q4 2022	200.00	3.00	3.00	14.61
Q1 2023	200.00	3.08	3.08	15.45
Q2 2023	200.00	3.12	3.12	14.70
Q3 2023	200.00	3.29	3.29	15.48
Q4 2023	200.00	3.29	3.29	16.39

Period	Shares Outstanding (M)	EPS (Riyal)	Adjusted EPS (Riyal)	Book Value (BV)
2014	200.00	1.20	1.08	5.14
2015	200.00	1.04	1.04	5.67
2016	200.00	1.29	1.29	6.38
2017	200.00	1.68	1.68	7.45
2018	200.00	1.80	1.80	8.56
2019	200.00	2.11	2.11	9.78
2020	200.00	2.64	2.64	11.40
2021	200.00	2.89	2.89	13.02
2022	200.00	3.00	3.00	14.61
2023	200.00	3.29	3.29	16.39

Multiple Ratios (End of Period Price)

Compared With The

Period	P/E	Adjusted P/E	Price/book
Q1 2014	21.78	21.78	4.75
Q2 2014	24.19	24.19	5.66
Q3 2014	26.21	28.82	6.43
Q4 2014	25.71	28.55	6.01
Q1 2015	27.98	31.11	6.15
Q2 2015	30.38	33.83	6.86
Q3 2015	29.89	30.21	5.68
Q4 2015	29.17	29.17	5.37
Q1 2016	25.75	25.75	4.78
Q2 2016	28.12	28.12	5.51
Q3 2016	25.07	25.07	4.84
Q4 2016	28.74	28.74	5.79
Q1 2017	26.02	26.02	5.23
Q2 2017	27.61	27.61	6.02
Q3 2017	25.29	25.29	5.71
Q4 2017	22.48	22.48	5.08
Q1 2018	24.64	24.64	5.48
Q2 2018	25.46	25.46	6.08
Q3 2018	22.23	22.23	5.10
Q4 2018	22.35	22.35	4.70
Q1 2019	22.22	22.22	4.41
Q2 2019	24.74	24.74	5.19
Q3 2019	23.35	23.35	4.80
Q4 2019	20.90	20.90	4.50
Q1 2020	19.79	19.79	4.05
Q2 2020	20.19	20.19	4.56
Q3 2020	24.26	24.26	5.84
Q4 2020	26.13	26.13	6.05
Q1 2021	27.67	27.67	6.47
Q2 2021	30.39	30.39	7.78
Q3 2021	31.51	31.51	7.36
Q4 2021	30.06	30.06	6.67
Q1 2022	36.58	36.58	7.72
Q2 2022	36.64	36.64	8.13
Q3 2022	35.30	35.30	7.22
Q4 2022	34.87	34.87	7.15
Q1 2023	38.17	38.17	7.61
Q2 2023	38.73	38.73	8.23
Q3 2023	31.26	31.26	6.65
Q4 2023	34.00	34.00	6.82

Period	P/E	Adjusted P/E	Price/book
2014	25.71	28.55	6.01
2015	29.17	29.17	5.37
2016	28.74	28.74	5.79
2017	22.48	22.48	5.08
2018	22.35	22.35	4.70
2019	20.90	20.90	4.50
2020	26.13	26.13	6.05
2021	30.06	30.06	6.67
2022	34.87	34.87	7.15
2023	34.00	34.00	6.82

Business Segments (Million)

Compared With The

Period	Medical Services	Pharmaceutical Products	Administration Fees
Q1 2014	196.67	46.87	-
Q2 2014	198.14	46.10	-
Q3 2014	186.70	43.78	-
Q4 2014	137.05	48.48	-
Q1 2015	201.34	52.07	-
Q2 2015	205.21	49.89	-
Q3 2015	189.98	41.65	-
Q4 2015	213.59	46.36	-
Q1 2016	251.45	52.14	-
Q2 2016	250.70	49.51	-
Q3 2016	235.92	44.32	-
Q4 2016	306.32	52.87	-
Q1 2017	310.82	52.15	-
Q2 2017	301.62	51.62	-
Q3 2017	308.40	51.07	-
Q4 2017	368.74	62.71	-
Q1 2018	360.78	61.57	-
Q2 2018	341.76	52.59	-
Q3 2018	345.96	58.31	-
Q4 2018	393.17	62.87	-
Q1 2019	396.75	65.87	-
Q2 2019	385.57	60.69	-
Q3 2019	384.03	59.26	-
Q4 2019	430.78	74.26	-
Q1 2020	425.64	68.31	-
Q2 2020	418.91	49.52	-
Q3 2020	490.26	58.80	-
Q4 2020	466.26	67.33	-
Q1 2021	466.09	68.04	-
Q2 2021	458.49	68.21	-
Q3 2021	464.53	66.45	-
Q4 2021	477.03	75.29	-
Q1 2022	490.92	76.05	-
Q2 2022	479.56	78.30	-
Q3 2022	475.20	73.95	-
Q4 2022	568.80	91.34	-
Q1 2023	569.92	94.30	-
Q2 2023	536.21	91.12	-
Q3 2023	549.93	90.96	-
Q4 2023	656.49	116.57	-

Period	Medical Services	Pharmaceutical Products	Administration Fees
2014	718.55	185.23	-
2015	810.12	189.96	-
2016	1,044.39	198.83	-
2017	1,289.59	217.55	-
2018	1,441.68	235.34	-
2019	1,597.13	260.08	-
2020	1,801.07	243.96	-
2021	1,866.15	277.98	-
2022	2,014.48	319.64	-
2023	2,312.55	392.95	-

Analysts Estimates (Million)

Item	Q4 2023 (e)	Q4 2023 (a)	Change‬
Average	193.07	184.17	(4.6 %)

Estimates vs Actual (Million)

Item	Q4 2023 (e)	Q4 2023 (a)	Change
OSOOL AND BAKHEET	184.81	184.17	(0.3) %
SNB Capital	186.00	184.17	(1.0) %
AlJazira Capital	182.20	184.17	1.1 %
Al Rajhi Capital	181.00	184.17	1.7 %
U-Capital	189.60	184.17	(2.9) %
Riyad Capital	203.00	184.17	(9.3) %
Sico	163.00	184.17	13.0 %
Goldman Sachs	212.00	184.17	(13.1) %
Hermes	236.00	184.17	(22.0) %

Financial Ratios

	Current
Market Cap (M Riyal)	18,480.00
Enterprise Value (EV) (M)	19,300.65
Shares Outstanding ((M))	200.00
EPS ( Riyal) (TTM)	3.29
Book Value (BV) ( Riyal)	17.66
Par Value ( Riyal)	10.00
Adjusted P/E (Last12)	28.08
P/E (TTM)	28.08
Price/book	5.23
Return on Average Assets (%) (TTM)	13.0
Return on Average Equity (%) (TTM)	19.9

Mouwasat Medical Services Co. (MOUWASAT)

Twitter

Facebook

Linked in

Comments {{getCommentCount()}}

Be the first to comment

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

Sorry: the validity period has ended to comment on this news

Opinions expressed in the comments section do not reflect the views of Argaam. Abusive comments of any kind will be removed. Political or religious commentary will not be tolerated.

Mouwasat 2023 profit up 10% to SAR 657.7M; Q4 at SAR 184.2M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million)

Revenue by Business Segment (Latest) 2023 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Mouwasat Medical Services Co. (MOUWASAT)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

×

Mouwasat 2023 profit up 10% to SAR 657.7M; Q4 at SAR 184.2M

View other reports

Financials (M)

Current Quarter Comparison (M)

Financial results (Million)

Financial results (Million)

Profit Performance (Million)

Profit Performance (Million)

Profitability

Profitability

Per Share Data (Riyal)

Per Share Data (Riyal)

Multiple Ratios (End of Period Price)

Ratios And Multiples

Business Segments (Million) Q4 2023

Revenue by Business Segment (Latest) 2023 Q4

Analysts Estimates (Million)

Analysts Estimates (Million)

Estimates vs Actual (Million)

Estimates Accuracy

Financial Ratios

Share Price

Mouwasat Medical Services Co. (MOUWASAT)

Comments {{getCommentCount()}}

رد{{comment.DisplayName}} على {{getCommenterName(comment.ParentThreadID)}}

{{comment.DisplayName}}

Business Segments (Million)